Literature DB >> 1651738

Influence of age and dose on the end-organ responses to atrial natriuretic peptide in humans.

B A Clark1, D Elahi, R P Shannon, J Y Wei, F H Epstein.   

Abstract

To test the hypothesis that age differentially affects the natriuretic, hemodynamic, and humoral response to exogenous ANP, we studied seven young (Y, 20 to 39 years) and five old (O, 65 to 83 years) healthy, normotensive, nonobese men during infusion of synthetic human ANP1,28 at two different rates: 1) 0.05 microgram/kg/min (high dose) for 1 h and 2) 0.005 microgram/kg/min (low dose) for 1 h. Compared to young, the old had higher basal ANP levels (O = 142 +/- 41 v Y = 29 +/- 4 pmol/L, P less than .025), achieved higher plasma levels with low-dose infusion (O = 327 +/- 24 v Y = 155 +/- 37 pmol/L, P less than .001) and had a longer ANP half-life (O = 7.8 +/- 0.6 v Y = 4.3 +/- 0.6 min, P less than .001), suggesting decreased catabolism in the old compared to the young. Despite these age-related differences in ANP levels, there was no difference in urinary sodium or cyclic GMP excretion. After termination of the low-dose infusion, plasma ANP and urinary cGMP promptly returned to baseline levels. Despite this, a sustained natriuresis (2-fold above control) was observed for 3 h in both groups. Low-dose infusion was associated with sustained suppression of aldosterone with minimal hemodynamic changes. During high-dose infusions there was no difference in natriuresis or peak ANP levels between the two groups (O = 1299 +/- 93 v Y = 1140 +/- 54 pmol/L). In contrast to the low-dose infusion, the high-dose infusion produced a transient natriuresis lasting only for the duration of the infusion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651738     DOI: 10.1093/ajh/4.6.500

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

1.  Possibility of age regulation of the natriuretic peptide C-receptor in human platelets.

Authors:  D Giannessi; M G Andreassi; S Del Ry; A Clerico; M G Colombo; N Dini
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

2.  Sodium disorders in the elderly.

Authors:  Naureen Tareen; David Martins; Glenn Nagami; Barton Levine; Keith C Norris
Journal:  J Natl Med Assoc       Date:  2005-02       Impact factor: 1.798

3.  Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease.

Authors:  Imran Uraizee; Susan Cheng; Chung-Lieh Hung; Anil Verma; James D Thomas; Michael R Zile; Gerard P Aurigemma; Scott D Solomon
Journal:  Am J Hypertens       Date:  2013-06-22       Impact factor: 2.689

Review 4.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

5.  N-terminal pro B-type natriuretic peptide (NT-proBNP): a possible surrogate of biological age in the elderly people.

Authors:  Antonio Muscari; Giampaolo Bianchi; Paola Forti; Donatella Magalotti; Paolo Pandolfi; Marco Zoli
Journal:  Geroscience       Date:  2020-08-11       Impact factor: 7.713

6.  Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study.

Authors:  L Lorgis; M Zeller; G Dentan; P Sicard; P Buffet; I L'Huillier; J C Beer; M Vincent-Martin; H Makki; P Gambert; Y Cottin
Journal:  BMJ       Date:  2009-05-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.